Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026

Mon, 03 Aug 2026 16:05:00 -0400

MIAMI, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report 2026 second quarter financial results and provide a business update on Wednesday, August 12, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.

Conference Call and Webcast Details:

Conference Call Number:

1.877.407.0789

Conference ID:

13761959

Call

Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026

Mon, 03 Aug 2026 16:05:00 -0400

Conference Call and Webcast Details:

Conference Call Number:

1.877.407.0789

Conference ID:

13761959

Call

Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026

Mon, 03 Aug 2026 16:05:00 -0400

Conference Call and Webcast Details:

Conference Call Number:

1.877.407.0789

Conference ID:

13761959

Call

Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026

Mon, 03 Aug 2026 16:05:00 -0400

Conference Call and Webcast Details:

Conference Call Number:

1.877.407.0789

Conference ID:

13761959

Call

Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026

Mon, 03 Aug 2026 16:05:00 -0400

Conference Call and Webcast Details:

Conference Call Number:

1.877.407.0789

Conference ID:

13761959

Call

Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026

Mon, 03 Aug 2026 16:05:00 -0400

Conference Call and Webcast Details:

Conference Call Number:	1.877.407.0789
Conference ID:	13761959

Call Form 8-K Longeveron Inc. For: Jul 24 Wed, 29 Jul 2026 16:02:00 -0400 si-local-file:///var/storage/secattach/20260729/26834732.html Form 8-K Longeveron Inc. For: Jul 24 Wed, 29 Jul 2026 16:02:00 -0400 si-local-file:///var/storage/secattach/20260729/26834732.html Form 3 Longeveron Inc. For: Jul 13 Filed by: Washburn Marie Wed, 29 Jul 2026 15:46:00 -0400 si-local-file:///var/storage/secattach/20260729/26834598.html Form 3 Longeveron Inc. For: Jul 13 Filed by: Washburn Marie Wed, 29 Jul 2026 15:46:00 -0400 si-local-file:///var/storage/secattach/20260729/26834598.html Longeveron adds Dr. Deborah Ascheim to its board of directors Thu, 23 Jul 2026 09:15:17 -0400 Longeveron Inc. (NASDAQ: LGVN) announced the election of Deborah D. Ascheim, M.D., to its board of directors, according to a company statement released July 23, 2026. Dr. Ascheim has more than 30 years of clinical and executive experience in gene, cell, and biologics therapies. She currently serves as fractional chief medical officer at Rejuvenate Bio, Inc., a clinical-stage biotech developing gene therapies for age-related diseases, and is founder and president of d2a Ltd., an independent consulting firm. She also serves on the advisory board of the Mass General Brigham Gene and Cell Therapy Institute. Prior to her current roles, Dr. Ascheim served Longeveron adds Dr. Deborah Ascheim to its board of directors Thu, 23 Jul 2026 09:15:17 -0400 Longeveron Inc. (NASDAQ: LGVN) announced the election of Deborah D. Ascheim, M.D., to its board of directors, according to a company statement released July 23, 2026. Dr. Ascheim has more than 30 years of clinical and executive experience in gene, cell, and biologics therapies. She currently serves as fractional chief medical officer at Rejuvenate Bio, Inc., a clinical-stage biotech developing gene therapies for age-related diseases, and is founder and president of d2a Ltd., an independent consulting firm. She also serves on the advisory board of the Mass General Brigham Gene and Cell Therapy Institute. Prior to her current roles, Dr. Ascheim served Longeveron adds Dr. Deborah Ascheim to its board of directors Thu, 23 Jul 2026 09:15:17 -0400 Longeveron Inc. (NASDAQ: LGVN) announced the election of Deborah D. Ascheim, M.D., to its board of directors, according to a company statement released July 23, 2026. Dr. Ascheim has more than 30 years of clinical and executive experience in gene, cell, and biologics therapies. She currently serves as fractional chief medical officer at Rejuvenate Bio, Inc., a clinical-stage biotech developing gene therapies for age-related diseases, and is founder and president of d2a Ltd., an independent consulting firm. She also serves on the advisory board of the Mass General Brigham Gene and Cell Therapy Institute. Prior to her current roles, Dr. Ascheim served Longeveron adds Dr. Deborah Ascheim to its board of directors Thu, 23 Jul 2026 09:15:17 -0400 Longeveron Inc. (NASDAQ: LGVN) announced the election of Deborah D. Ascheim, M.D., to its board of directors, according to a company statement released July 23, 2026. Dr. Ascheim has more than 30 years of clinical and executive experience in gene, cell, and biologics therapies. She currently serves as fractional chief medical officer at Rejuvenate Bio, Inc., a clinical-stage biotech developing gene therapies for age-related diseases, and is founder and president of d2a Ltd., an independent consulting firm. She also serves on the advisory board of the Mass General Brigham Gene and Cell Therapy Institute. Prior to her current roles, Dr. Ascheim served Longeveron adds Dr. Deborah Ascheim to its board of directors Thu, 23 Jul 2026 09:15:17 -0400 Longeveron Inc. (NASDAQ: LGVN) announced the election of Deborah D. Ascheim, M.D., to its board of directors, according to a company statement released July 23, 2026. Dr. Ascheim has more than 30 years of clinical and executive experience in gene, cell, and biologics therapies. She currently serves as fractional chief medical officer at Rejuvenate Bio, Inc., a clinical-stage biotech developing gene therapies for age-related diseases, and is founder and president of d2a Ltd., an independent consulting firm. She also serves on the advisory board of the Mass General Brigham Gene and Cell Therapy Institute. Prior to her current roles, Dr. Ascheim served Longeveron adds Dr. Deborah Ascheim to its board of directors Thu, 23 Jul 2026 09:15:17 -0400 Longeveron Inc. (NASDAQ: LGVN) announced the election of Deborah D. Ascheim, M.D., to its board of directors, according to a company statement released July 23, 2026. Dr. Ascheim has more than 30 years of clinical and executive experience in gene, cell, and biologics therapies. She currently serves as fractional chief medical officer at Rejuvenate Bio, Inc., a clinical-stage biotech developing gene therapies for age-related diseases, and is founder and president of d2a Ltd., an independent consulting firm. She also serves on the advisory board of the Mass General Brigham Gene and Cell Therapy Institute. Prior to her current roles, Dr. Ascheim served Longeveron adds Dr. Deborah Ascheim to its board of directors Thu, 23 Jul 2026 09:15:17 -0400 Longeveron Inc. (NASDAQ: LGVN) announced the election of Deborah D. Ascheim, M.D., to its board of directors, according to a company statement released July 23, 2026. Dr. Ascheim has more than 30 years of clinical and executive experience in gene, cell, and biologics therapies. She currently serves as fractional chief medical officer at Rejuvenate Bio, Inc., a clinical-stage biotech developing gene therapies for age-related diseases, and is founder and president of d2a Ltd., an independent consulting firm. She also serves on the advisory board of the Mass General Brigham Gene and Cell Therapy Institute. Prior to her current roles, Dr. Ascheim served Longeveron adds Dr. Deborah Ascheim to its board of directors Thu, 23 Jul 2026 09:15:17 -0400 Longeveron Inc. (NASDAQ: LGVN) announced the election of Deborah D. Ascheim, M.D., to its board of directors, according to a company statement released July 23, 2026. Dr. Ascheim has more than 30 years of clinical and executive experience in gene, cell, and biologics therapies. She currently serves as fractional chief medical officer at Rejuvenate Bio, Inc., a clinical-stage biotech developing gene therapies for age-related diseases, and is founder and president of d2a Ltd., an independent consulting firm. She also serves on the advisory board of the Mass General Brigham Gene and Cell Therapy Institute. Prior to her current roles, Dr. Ascheim served Longeveron adds Dr. Deborah Ascheim to its board of directors Thu, 23 Jul 2026 09:15:17 -0400 Longeveron Inc. (NASDAQ: LGVN) announced the election of Deborah D. Ascheim, M.D., to its board of directors, according to a company statement released July 23, 2026. Dr. Ascheim has more than 30 years of clinical and executive experience in gene, cell, and biologics therapies. She currently serves as fractional chief medical officer at Rejuvenate Bio, Inc., a clinical-stage biotech developing gene therapies for age-related diseases, and is founder and president of d2a Ltd., an independent consulting firm. She also serves on the advisory board of the Mass General Brigham Gene and Cell Therapy Institute. Prior to her current roles, Dr. Ascheim served Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors Thu, 23 Jul 2026 09:15:00 -0400 MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that Deborah D. Ascheim, M.D., has been elected to the Longeveron Board of Directors. Dr. Ascheim is a strategic biotech Chief Medical Officer and physician who has over 30 years of clinical and executive experience advancing breakthrough therapies, including gene, cell, and biologics, for rare, ultra-rare, and common diseases across multiple indications. “I am delighted to welcome Deborah, with her impressive development Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors Thu, 23 Jul 2026 09:15:00 -0400 MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that Deborah D. Ascheim, M.D., has been elected to the Longeveron Board of Directors. Dr. Ascheim is a strategic biotech Chief Medical Officer and physician who has over 30 years of clinical and executive experience advancing breakthrough therapies, including gene, cell, and biologics, for rare, ultra-rare, and common diseases across multiple indications. “I am delighted to welcome Deborah, with her impressive development Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors Thu, 23 Jul 2026 09:15:00 -0400 MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that Deborah D. Ascheim, M.D., has been elected to the Longeveron Board of Directors. Dr. Ascheim is a strategic biotech Chief Medical Officer and physician who has over 30 years of clinical and executive experience advancing breakthrough therapies, including gene, cell, and biologics, for rare, ultra-rare, and common diseases across multiple indications. “I am delighted to welcome Deborah, with her impressive development Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors Thu, 23 Jul 2026 09:15:00 -0400 MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that Deborah D. Ascheim, M.D., has been elected to the Longeveron Board of Directors. Dr. Ascheim is a strategic biotech Chief Medical Officer and physician who has over 30 years of clinical and executive experience advancing breakthrough therapies, including gene, cell, and biologics, for rare, ultra-rare, and common diseases across multiple indications. “I am delighted to welcome Deborah, with her impressive development Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors Thu, 23 Jul 2026 09:15:00 -0400 MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that Deborah D. Ascheim, M.D., has been elected to the Longeveron Board of Directors. Dr. Ascheim is a strategic biotech Chief Medical Officer and physician who has over 30 years of clinical and executive experience advancing breakthrough therapies, including gene, cell, and biologics, for rare, ultra-rare, and common diseases across multiple indications. “I am delighted to welcome Deborah, with her impressive development Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors Thu, 23 Jul 2026 09:15:00 -0400 MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that Deborah D. Ascheim, M.D., has been elected to the Longeveron Board of Directors. Dr. Ascheim is a strategic biotech Chief Medical Officer and physician who has over 30 years of clinical and executive experience advancing breakthrough therapies, including gene, cell, and biologics, for rare, ultra-rare, and common diseases across multiple indications. “I am delighted to welcome Deborah, with her impressive development

StreetInsider.com News Articles

Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026

Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026

Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026

Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026

Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026

Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026

Form 8-K Longeveron Inc. For: Jul 24

Form 8-K Longeveron Inc. For: Jul 24

Form 3 Longeveron Inc. For: Jul 13 Filed by: Washburn Marie

Form 3 Longeveron Inc. For: Jul 13 Filed by: Washburn Marie

Longeveron adds Dr. Deborah Ascheim to its board of directors

Longeveron adds Dr. Deborah Ascheim to its board of directors

Longeveron adds Dr. Deborah Ascheim to its board of directors

Longeveron adds Dr. Deborah Ascheim to its board of directors

Longeveron adds Dr. Deborah Ascheim to its board of directors

Longeveron adds Dr. Deborah Ascheim to its board of directors

Longeveron adds Dr. Deborah Ascheim to its board of directors

Longeveron adds Dr. Deborah Ascheim to its board of directors

Longeveron adds Dr. Deborah Ascheim to its board of directors

Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors

Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors

Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors

Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors

Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors

Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors